Back

Identification of Hyal2-expressing tumor-associated myeloid cells in cancer: implications for cancer-related inflammation through enhanced hyaluronan degradation

Dominguez, P. R. G.; Kwenda, E.; Donelan, W.; O'Malley, P.; Crispen, P. L.; Kusmartsev, S.

2020-09-14 cancer biology
10.1101/2020.09.14.296475 bioRxiv
Show abstract

Increased presence of myeloid derived suppressor cells (MDSCs) and tumor-associated macrophages (TAMs) in tumor tissue has been extensively reported. These cells represent a major constituent of tumor infiltrate and exhibit a distinct phenotype with immunosuppressive and tolerogenic functions. However, their role in the regulation of hyaluronan (HA) metabolism in the tumor microenvironment has not been established. Here we describe a novel function of tumor-associated myeloid cells related to the enhanced breakdown of extracellular HA in human bladder cancer tissue leading to accumulation of small HA fragments with MW <20 kDa. Increased fragmentation of extracellular HA and accumulation of low molecular weight HA (LMW-HA) in tumor tissue was associated with elevated production of multiple inflammatory cytokines, chemokines, and angiogenic factors. The fragmentation of HA by myeloid cells was mediated by the membrane-bound enzyme hyaluronidase 2 (Hyal2). The increased numbers of Hyal2+CD11b+ myeloid cells were detected in the tumor tissue as well as in the peripheral blood of bladder cancer patients. Co-expression of CD33 suggests that these cells belong to monocytic myeloid-derived suppressor cells. HA-degrading function of Hyal2-expressing MDSCs could be enhanced by exposure to tumor-conditioned medium, and IL-1{beta} was identified as one of factors involved in the stimulation of Hyal2 activity. CD44-mediated signaling plays an important role in the regulation of HA-degrading activity of Hyal2-expressing myeloid cells, since engagement of CD44 receptor with specific monoclonal antibody triggered translocation of Hyal2 enzyme to the cellular surface and also stimulated secretion of IL-1{beta}. Taken together, this work identifies the Hyal2-expressing tumor-associated myeloid cells, and links these cells to the accumulation of LMW-HA in the tumor microenvironment and cancer-related inflammation and angiogenesis.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

1
Cancers
200 papers in training set
Top 0.2%
12.4%
2
Molecular Cancer Research
42 papers in training set
Top 0.1%
6.9%
3
Scientific Reports
3102 papers in training set
Top 17%
6.4%
4
Frontiers in Oncology
95 papers in training set
Top 0.7%
4.9%
5
International Journal of Molecular Sciences
453 papers in training set
Top 2%
4.3%
6
PLOS ONE
4510 papers in training set
Top 38%
3.7%
7
Frontiers in Immunology
586 papers in training set
Top 2%
3.6%
8
Cells
232 papers in training set
Top 0.9%
3.1%
9
Frontiers in Cell and Developmental Biology
218 papers in training set
Top 2%
2.8%
10
Oncogene
76 papers in training set
Top 0.7%
2.5%
50% of probability mass above
11
Cell Death Discovery
51 papers in training set
Top 0.4%
2.1%
12
Journal of Leukocyte Biology
40 papers in training set
Top 0.2%
2.1%
13
Oncotarget
15 papers in training set
Top 0.1%
1.9%
14
Molecular Oncology
50 papers in training set
Top 0.3%
1.8%
15
Neoplasia
22 papers in training set
Top 0.2%
1.7%
16
Clinical Epigenetics
53 papers in training set
Top 0.5%
1.7%
17
OncoImmunology
22 papers in training set
Top 0.2%
1.7%
18
Journal of Cellular and Molecular Medicine
18 papers in training set
Top 0.4%
1.7%
19
Biomedicines
66 papers in training set
Top 1%
1.5%
20
International Journal of Cancer
42 papers in training set
Top 0.8%
1.2%
21
BMC Cancer
52 papers in training set
Top 2%
1.0%
22
Cell Communication and Signaling
35 papers in training set
Top 1.0%
0.8%
23
The Journal of Immunology
146 papers in training set
Top 1%
0.8%
24
Disease Models & Mechanisms
119 papers in training set
Top 2%
0.8%
25
The Journal of Pathology
22 papers in training set
Top 0.5%
0.8%
26
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.4%
0.8%
27
Cancer Research
116 papers in training set
Top 3%
0.8%
28
Aging
69 papers in training set
Top 3%
0.8%
29
Cancer Research Communications
46 papers in training set
Top 1%
0.8%
30
Cell Death & Disease
126 papers in training set
Top 3%
0.8%